Health-related quality-of-life and treatment targets in myasthenia gravis

Muscle and Nerve

Volumn 50, Issue 4, 2014, Pages 493-500

  Utsugisawa, Kimiaki ^a   Suzuki, Shigeaki ^b   Nagane, Yuriko ^a   Masuda, Masayuki ^c   Murai, Hiroyuki ^d   Imai, Tomihiro ^e   Tsuda, Emiko ^e   Konno, Shingo ^f   Nakane, Shunya ^g   Suzuki, Yasushi ^h   Fujihara, Kazuo ⁱ   Suzuki, Norihiro ^b  

^a Hanamaki General Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d ASO IIZUKA HOSPITAL   (Japan)

^e SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f TOHO UNIVERSITY   (Japan)

^g Nagasaki Kawatana Medical Center   (Japan)

^h SENDAI CITY MEDICAL CENTER   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoimmune diseases; Cohort studies; Myasthenia; Quality of life; Treatment

Indexed keywords

PREDNISOLONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CUSHINGOID SYNDROME; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; HEALTH STATUS; JAPAN; LONGITUDINAL STUDY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PSYCHOLOGY; SELF CONCEPT; SEVERITY OF ILLNESS INDEX; STATISTICS;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; QUALITY OF LIFE; SELF CONCEPT; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 84922479558     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24213     Document Type: Article

References (24)

1. Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother 2009;9:351-358.
2. Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010;43:428-435.
3. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298.
4. Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 2012;46:166-173.
5. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.
6. Padua L, Evoli A, Apirile I, Cliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001;22:363-369.
7. Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001;24:512-516.
8. Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve 2010;42:5-13.
9. Jaretzki A3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. for the Task Force of the Medical Scientific Advisory Board of Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standers. Neurology 2000;55:16-23.
10. Burns TM, Conaway MR, Cutter GR, Sanders DB, and the Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008;38:957-963.
11. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB, the MG Composite and MG-QOL15 Study Group. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve 2010;41:219-226.
12. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB, the MG Composite and MG-QOL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 2011;43:14-18.
13. Burns TM, Conaway MR, Cutter GR, Sanders DB, and the Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008;38:1553-1562.
14. Burns TM, Conaway M, Sanders DB, on behalf of the MG Composite and MG-QOL15 Study Group. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010;74:1434-1440.
15. Suzuki S, Utsugisawa K, Suzuki N. Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 2013;84:989-994.
16. Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, et al. Factors associated with depressive state in patients with myasthenia gravis: a multicenter cross-sectional study. BMJ Open 2011;1:e000313.
17. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients. Eur Neurol 2010;64:186-190.
18. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 2011;65:16-22.
19. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann NY Acad Sci 2008;1132:238-243.
20. Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011;305:97-102.
21. Vincent A, Clover L, Buckley C, Grimley EJ, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74:1105-1108.
22. Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005;65:928-930.
23. Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM; MG Composite MG-QOL15 Study Group. Psychometric evaluation of the myasthenia gravis composite using Rasch analysis. Muscle Nerve 2012;45:820-825.
24. Barnett C, Wilson G, Barth D, Katzberg HD, Bril V. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 2013;84:94-97.